Inactive Instrument

Generex Biotechnology Corporation

Equities

GNBT

US3714853013

Biotechnology & Medical Research

Generex Biotechnology Corporation Announces Craig Lyman Tenders His Resignation from the Board of Directors

March 01, 2019 at 02:56 pm EST

On February 21, 2018, Craig Lyman tendered his resignation from the board of directors of Generex Biotechnology Corporation. Mr. Lyman indicated his availability to provide future consulting to the Company in his areas of expertise.

Latest news about Generex Biotechnology Corporation

Motion for Asset Sale Approved for Generex Biotechnology Corporation	Jan. 18	CI
Motion for Asset Sale Filed by Generex Biotechnology Corporation	Nov. 30	CI
Motion for Asset Sale Approved for Generex Biotechnology Corporation	23-01-12	CI
Amended Bidding Procedure Approved for Generex Biotechnology Corporation	23-01-09	CI
Involuntary Petition Approved for Generex Biotechnology Corporation	22-06-06	CI
Involuntary Petition Filed Against Generex Biotechnology Corporation	22-04-23	CI
Generex Biotechnology Corporation Enters into Quality Agreement with PPD Development, L.P	21-07-23	CI
Generex Biotechnology Corporation announced that it has received $1 million in funding	21-07-14	CI
Generex Biotechnology Corporation Reports Earnings Results for the Third Quarter Ended April 30, 2021	21-06-21	CI
Generex Biotechnology Corporation Subsidiary NuGenHealth Contracts with Westside Medicine & Cardiology, Inc. to Provide Remote Patient Monitoring Services	21-05-11	CI
Generex Provides Clarification on Its Ii-Key COVID-19 Complete Vaccine China Partnership Agreement	21-05-05	CI
Generex Provides Update on Its Ii-Key COVID-19 Complete Vaccine Program: Advancing Global Development	21-04-27	CI
Generex Biotechnology Corporation Reports Earnings Results for the Second Quarter Ended January 31, 2021	21-03-17	CI
Generex Biotechnology Corporation Completes Mouse Immunogenicity Study	21-02-24	CI
Generex Biotechnology Corporation announced that it has received $1.425 million in funding	21-02-16	CI
Transcript : Generex Biotechnology Corporation - Special Call	21-02-05
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for the Complete Vaccine™	20-12-31	CI
Generex Biotechnology Corporation Reports Earnings Results for the First Quarter Ended October 31, 2020	20-12-21	CI
Nugenerex Immuno-Oncology, Inc. and Generex Biotechnology Corporation Signs an Extension for the Receipt of the USD 5,000,000.00 Upfront Licensing Fee Payment	20-12-17	CI
Generex Biotechnology Corporation and Nugenerex Immuno-Oncology Grants Licensing Rights to Bintai Healthcare Sdn Bhd	20-11-25	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand	20-11-23	CI
Generex Biotechnology Corporation Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform	20-11-18	CI
Generex Biotechnology Corporation Reports Earnings Results for the Full Year Ended July 31, 2020	20-11-13	CI
Generex Announces the Signing of A Framework Agreement with the China Cdc, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co., Ltd on the Cooperative Development of Ii-Key Vaccines	20-11-04	CI
Generex Biotechnology Corporation appoints Tamera-Coyne Beasley to NGIO COVID-19 Vaccine Scientific & Clinical Advisory Board	20-10-30	CI

Chart Generex Biotechnology Corporation

Duration

Period

More charts

Company Profile

Generex Biotechnology Corporation is a life science holding company. The Company is engaged in pharmaceutical and biotechnological research and development and other activities. It is focused on building an organizational platform for the financing, development, commercialization and distribution of promising devices, biologics, therapeutic and diagnostic products to improve human health. The Company's subsidiary includes NuGenerex family of companies: NuGenerex Immuno-Oncology, Inc., NuGenerex Diagnostics, NuGenerex Health, LLC, NuGenerex Regenerative Medicine (NRM), NuGenerex Diagnostics (NGD), and NuGenerex Therapeutics. NuGenerex Immuno-Oncology, Inc. is a platform biotechnology company focused on improving the innate immune system to treat and prevent cancer and infectious disease with a pipeline of immunotherapy indications based on its patented platform technology.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+21.16%	127B
REGENERON PHARMACEUTICALS, INC.	+23.52%	116B
ARGENX SE	+25.15%	27.69B
BIONTECH SE	-19.35%	19.62B
GENMAB A/S	-16.57%	16.26B
BEIGENE, LTD.	-16.44%	15.49B
NEUROCRINE BIOSCIENCES, INC.	+11.79%	14.81B
WUXI APPTEC CO., LTD.	-46.65%	14.39B
SAREPTA THERAPEUTICS, INC.	+56.12%	14.11B

Bio Therapeutic Drugs